Could Extra Virgin Olive Oil Protect Against Fatty Liver — and Why Was the Signal Female-Specific?

Study Overview

The paper, “Extra Virgin Olive Oil Reduces the Risk of Non-Alcoholic Fatty Liver Disease in Females but Not in Males: Results from the NUTRIHEP Cohort,” was published in Nutrients in 2024 by Donghia, Tatoli, Campanella, Losurdo, Di Leo, De Pergola, Bonfiglio, and Giannelli. It is not a randomized trial. It is an observational cohort analysis from the NUTRIHEP study in Putignano, Bari, Italy.

The investigators analyzed 1,426 adults assessed at the second NUTRIHEP recall between 2014 and 2018. EVOO intake was estimated with the validated EPIC food-frequency questionnaire and divided into four daily intake quartiles: <2.30 g/day, 2.30–8.10 g/day, 8.10–19.10 g/day, and >19.10 g/day. NAFLD was diagnosed using liver ultrasound, while excluding alcoholic fatty liver by alcohol cutoffs of 30 g/day for men and 20 g/day for women, plus other secondary causes such as viral hepatitis and drug-induced fatty liver.

The critical design feature is sex stratification. Instead of assuming that EVOO behaves identically across the whole cohort, the authors built adjusted logistic-regression models separately for women and men. Models adjusted for age, cholesterol, BMI, smoking, daily alcohol intake, education, and job — a sensible set of covariates for a diet-and-liver outcome, though not enough to eliminate residual confounding.

Key Findings: The Actual Numbers

The headline result is narrow but striking. In women, compared with the reference group consuming less than 2.30 g/day of EVOO, the highest intake quartile above 19.10 g/day was associated with substantially lower odds of NAFLD: OR 0.43, standard error 0.15, p = 0.02, 95% CI 0.21 to 0.85. The middle quartiles moved in the same direction but did not reach significance: OR 0.90 for 2.30–8.10 g/day and OR 0.59 for 8.10–19.10 g/day.

Men did not show the same pattern. Their odds ratios were 1.26, 1.27, and 1.34 across increasing EVOO quartiles, all non-significant, with the highest quartile confidence interval crossing one widely (0.65 to 2.73; p = 0.42). Importantly, men entered the analysis with a more adverse metabolic profile: higher NAFLD prevalence, higher alcohol intake, higher systolic and diastolic blood pressure, higher insulin, HOMA, glucose, triglycerides, GOT, SGPT, GGT, and ferritin. That background makes the male null result hard to interpret as “EVOO does nothing for men.”

Mechanism: Why EVOO Could Matter for NAFLD

NAFLD is not simply fat sitting passively in the liver. The disease emerges when hepatic lipid uptake and de novo lipogenesis exceed fatty-acid oxidation and lipid export. That imbalance promotes oxidative stress, mitochondrial strain, inflammatory signaling, hepatocyte injury, and, in some people, progression toward steatohepatitis, fibrosis, cirrhosis, or hepatocellular carcinoma.

Extra virgin olive oil is biologically plausible because it changes several pressure points at once. Oleic acid replaces saturated fat in the diet, which may improve postprandial lipid handling and membrane lipid composition. EVOO phenolics — including hydroxytyrosol, tyrosol, oleocanthal, oleacein, and secoiridoid derivatives — can reduce lipid oxidation, support antioxidant defenses, and dampen inflammatory pathways such as NF-κB-related signaling. In practical terms, EVOO is not a “liver detox.” It is a food matrix that may reduce the metabolic and oxidative load that helps drive fatty liver progression.

The female-specific finding is the interesting wrinkle. The authors point toward sex differences in food intake, physiology, and potentially absorption. A more cautious interpretation is that sex may modify the relationship between EVOO and NAFLD through hormonal status, fat distribution, alcohol exposure, baseline insulin resistance, dietary substitution patterns, or unmeasured lifestyle variables. The study raises that question well; it does not fully answer it.

Context: How This Fits the Wider Literature

This paper fits a larger pattern: Mediterranean-style diets tend to look favorable for fatty liver, cardiometabolic risk, and inflammation, and EVOO is one of the defining fats in that pattern. Intervention studies in metabolic syndrome, diabetes, and postprandial metabolism suggest that olive-oil quality and phenolic content can influence oxidative stress, insulin resistance, lipoprotein oxidation, and inflammatory markers.

What this study adds is specificity around liver ultrasound and sex. Most consumer advice flattens “olive oil is healthy” into one universal claim. NUTRIHEP suggests the more precise question is: healthy for whom, at what dose, replacing what foods, and against which outcome? A >19.10 g/day signal is not extreme — it is roughly a tablespoon-plus per day — but the result appeared only after stratification.

It also complements, rather than replaces, randomized evidence. Cohorts can see real-life long-term patterns, but they are vulnerable to confounding. RCTs can isolate causality, but they are often short and may miss chronic liver outcomes. For fatty liver, the strongest future evidence would combine both: randomized Mediterranean/EVOO interventions with MRI- or ultrasound-confirmed liver fat endpoints, sex-stratified analysis, and measured phenolic exposure.

Limitations

• • Observational design: adjusted odds ratios are not proof of causality.
• • Single-region cohort: Putignano, Bari is a Mediterranean setting; results may not transfer directly to populations with different diets.
• • Diet measurement error: EVOO intake came from a food-frequency questionnaire, not weighed intake or biomarkers.
• • No phenolic chemistry: the study measured grams of EVOO, not polyphenol concentration, freshness, cultivar, or storage quality.
• • Sex-stratified surprise: the female signal is compelling but needs replication; subgroup findings can be unstable.
• • Ultrasound endpoint: ultrasound is clinically useful but less precise than MRI-PDFF for quantifying liver fat.

Our Take

This is a good, not definitive, paper. The result is worth bookmarking because it is clinically relevant, uses ultrasound-defined NAFLD, includes 1,426 real-world adults, and reports a clear adjusted effect size. An OR of 0.43 in women is not trivial. If replicated, it would make EVOO one of the more practical food-level signals in fatty-liver prevention.

The weakness is causality. People who consume more EVOO may differ in many ways that are difficult to fully adjust away: diet quality, cooking habits, socioeconomic status, health consciousness, alcohol pattern, and medical surveillance. The best interpretation is not “EVOO cures fatty liver.” It is: higher habitual EVOO intake, especially above about 20 g/day, is associated with meaningfully lower NAFLD odds in women in this Italian cohort, and the biology is plausible enough to justify stronger sex-stratified intervention trials.

Reference

Donghia R, Tatoli R, Campanella A, Losurdo G, Di Leo A, De Pergola G, Bonfiglio C, Giannelli G. Extra Virgin Olive Oil Reduces the Risk of Non-Alcoholic Fatty Liver Disease in Females but Not in Males: Results from the NUTRIHEP Cohort. Nutrients. 2024;16(19):3234. doi: 10.3390/nu16193234. PMID: 39408202. Full text: PMC11478343.